| Terminated | A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) NCT05121948 | HiberCell, Inc. | Phase 1 |
| Completed | Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer NCT03081858 | Lipac Oncology LLC | Phase 1 / Phase 2 |
| Unknown | Biomarkers in Urothelial Cancer Patients Treated With Pembrolizumab NCT03263039 | Erasmus Medical Center | Phase 2 |
| Completed | A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer NCT02897765 | BioNTech US Inc. | Phase 1 |
| Completed | Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors NCT02318329 | Five Prime Therapeutics, Inc. | Phase 1 |
| Completed | A Laser Detection for Bladder Cancer by (Photodynamic) Spectra of Urine NCT02101931 | Princess Al-Johara Al-Ibrahim Cancer Research Center | Phase 3 |
| Terminated | Adjuvant Radiation for High Risk Bladder Cancer NCT01954173 | Emory University | N/A |
| Withdrawn | Gemcitabine Hydrochloride and Cisplatin or High-Dose Methotrexate, Vinblastine, Doxorubicin Hydrochloride, and NCT01639521 | University of Southern California | Phase 2 |
| Terminated | Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder NCT01382706 | University of Southern California | Phase 2 |
| Terminated | Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Biliary, Pancreatic, Ur NCT01282333 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Broccoli Sprout Extract in Treating Patients With Transitional Cell Bladder Cancer Undergoing Surgery NCT01108003 | Roswell Park Cancer Institute | N/A |
| Terminated | Neoadjuvant Cisplatin, Gemcitabine, Sunitinib Malate + Radical Cystectomy for TCC NCT00859339 | Noah Hahn, M.D. | Phase 2 |
| Terminated | Sunitinib Malate in Treating Patients With Recurrent Transitional Cell Bladder Cancer NCT01118351 | Case Comprehensive Cancer Center | Phase 2 |
| Completed | Pazopanib in Treating Patients With Metastatic Urothelial Cancer NCT00471536 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Neoadjuvant Dasatinib and Radical Cystectomy for Transitional Cell Carcinoma of the Bladder NCT00706641 | Hoosier Cancer Research Network | N/A |
| Completed | Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Functi NCT00478361 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium NCT00407485 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Prostate Capsule Sparing Cystectomy and Nerve-sparing Radical Cystoprostatectomy in Men With Bladder Cancer NCT01824329 | University of Michigan | Phase 2 |
| Terminated | Vorinostat in Treating Patients With Locally Recurrent or Metastatic Cancer of the Urothelium NCT00363883 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium NCT00112905 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Sorafenib in Treating Patients With Advanced or Metastatic Cancer of the Urinary Tract NCT00112671 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Efficacy of Combination of Trastuzumab to Gemcitabine - Platinum Advanced or Metastatic Urothelial Carcinoma NCT01828736 | Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie | Phase 2 |
| Completed | Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transition NCT00072150 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Trastuzumab in Treating Patients With Previously Treated, Locally Advanced, or Metastatic Cancer of the Urothe NCT00004856 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Comparison of Immediate and Delayed Adjuvant Chemotherapy in Treating Patients Who Have Undergone a Radical Cy NCT00028756 | European Organisation for Research and Treatment of Cancer - EORTC | Phase 3 |
| Completed | Ixabepilone in Treating Patients With Advanced Urinary Tract Cancer NCT00021099 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Arsenic Trioxide in Treating Patients With Urothelial Cancer NCT00009867 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Trastuzumab and Combination Chemotherapy in Treating Patients With Locally Recurrent or Metastatic Urinary Tra NCT00005831 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Gene Therapy in Treating Patients With Advanced Bladder Cancer NCT00003167 | National Cancer Institute (NCI) | Phase 1 |